Results 111 to 120 of about 22,516 (228)

CRPC-DB a Discourse Bank for Portuguese

, 2022
Amália Mendes, Pierre Lejeune
openaire   +2 more sources

Hormonal regulation of the osteogenic signature in bone metastatic Castration-Resistant Prostate Cancer (CRPC)

, 2023
Bone is the most preferred site for prostate cancer (PCa) metastasis which is a significant cause of cancer-related death in men. Bone metastasis in PCa typically forms sclerotic lesions, i.e., an increase in abnormal bone mass, unlike, for example ...
Sankar Perumal, Sowndharya
core  

Pericytes in castration-resistant prostate cancer associated with disease progression and immunotherapy response: insights from single-cell analysis

Cancer Cell International
Background The current immunotherapeutic strategies yield limited therapeutic benefits in patients with castration-resistant prostate cancer (CRPC) due to its immunologically “cold” tumor milieu.
Yifeng Qiu, Yuhan Wang, Jiahe Liu, Kai Sun, Shigeo Horie, Zhitong Bing, Qi Hou   +6 more
doaj   +1 more source

Perspectives on CRPC treatment -enzalutamide is promised as a first option for CRPC treatment-

Annals of Oncology, 2016
Go Kimura, Yukihiro Kondo
openaire   +1 more source

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

, 2018
Purpose: Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently required.
Alec Paschalis, Ines Figueiredo, Adam Sharp, Wendy S. Halsey, Amanda Swain, Jian Ning, Wei Yuan, Arul M. Chinnaiyan, Jonathan Welti, Gunther Boysen, Suzanne Carreira, Johann S. de Bono, Veronica Gil, Stephen R. Plymate, Semini Sumanasuriya, Mateus Crespo, George Seed, Daniel Nava Rodrigues, Eleanor Knight, Ganesh V. Raj, David Dolling, Matthew Clarke, Antje Neeb, Jeffrey C. Francis, Ashley Hughes, Ram S. Mani   +25 more
core   +1 more source

Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel

Discover Oncology
Castration-resistant prostate cancer (CRPC) represents the final stage of prostate cancer (PCa). Cabazitaxel, a taxane chemotherapy drug, is used in treating CRPC.
Haopeng Li, Xin’an Wang, Menghe Zhai, Chengdang Xu, Xi Chen   +4 more
doaj   +1 more source

SNRPA upregulation promotes mitochondrial function and drives CRPC aggressiveness

Cell Death and Disease
Identifying novel molecular targets for castration-resistant prostate cancer (CRPC) is crucial. This study examines the expression and functional role of small nuclear ribonucleoprotein polypeptide A (SNRPA), a core component of the U1 snRNP complex, in ...
Xiao-long Liu, Lu Jin, Yong-qiang Yang, Mei-hua Lu, Bo-xin Xue   +4 more
doaj   +1 more source

AVPR1A: a target in CRPC? [PDF]

Nature Reviews Urology, 2019
openaire   +2 more sources

CRPC [PDF]

, 2011
openaire   +1 more source

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

, 2009
Prostate cancer is a common disease affecting males. Despite initial sensitivity to hormone treatment, prostate cancer eventually progresses to a castration-resistant stage (CRPC), which carries an ominous prognosis.
Skolarikos, A., Deliveliotis, C., Mitsogiannis, I.C.   +2 more
core   +1 more source